Form 4 for AXGN Axogen, Inc.
Accepted 2021-12-22 00:00:00 ET · period of report 2021-12-20 · accession 0000805928-21-000173 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-12-22 | 2021-12-20 | AXGN | DeVinney Erick Wayne | VP Peripheral Nerve Science | F - Tax | $9.24 | -144 | 86.7K | -0.2% | -$1,331 |
| D | 2021-12-22 | 2021-12-20 | AXGN | DeVinney Erick Wayne | VP Peripheral Nerve Science | M - OptEx | $0.00 | +575 | 86.8K | +0.7% | $0 |
| D | 2021-12-22 | 2021-12-20 | AXGN | DeVinney Erick Wayne | VP Peripheral Nerve Science | M - OptEx | $0.00 | -575 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-20 | F | D | 144 | $9.24 | 86,686 | D | — | — | (F2) Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units on December 18, 2021. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| 2 | Common | Common Stock | 2021-12-20 | M | A | 575 | $0.00 | 86,830 | D | — | — | (F1) This reflects the number of restricted stock units that became vested as of December 18, 2021. |
| 3 | Derivative | Restricted Stock Units | 2021-12-20 | M | D | 575 | $0.00 | 0 | D | $0.00 · 2021-12-20 to 2021-12-20 | 575 Common Stock | (F3) Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. (F4) All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. |